Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study - Ding, Jie; Jiang, Xianguo; Cai, Yu; Pan, Shuting; Deng, Ye; Gao, Meichun; Lin, Yan; Zhao, Nan; Wang, Ze; Yu, Haojun; Qiu, Huiying; Jin, Yuyan; et al. (CNS neuroscience & therapeutics, 2022)
Keywords: Antibodies; Apheresis; Aquaporin 4; Blood tests; Cell activation; clinical study; Disease; Drug dosages; effectiveness; Immunoglobulins; Immunosuppressive agents; Immunotherapy; Latency; Leukocytes (neutrophilic); Ligands; Lymphocytes; Lymphocytes B; Nervous system; Neuromyelitis; neuromyelitis optica spectrum disorders; Original; Patients; Plasma; plasma exchange; Safety; Telitacicept; Tomography; Tumor necrosis factor-TNF; Urine; Visual evoked potentials